|
SPTLC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.57880000026556E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.52035999999578E-05 |
| Normal-vs-Stage2 |
1.657080E-03 |
| Normal-vs-Stage3 |
7.68069996492926E-09 |
| Normal-vs-Stage4 |
2.56980003943141E-09 |
| Stage1-vs-Stage2 |
5.746200E-01 |
| Stage1-vs-Stage3 |
1.116900E-03 |
| Stage1-vs-Stage4 |
4.816400E-04 |
| Stage2-vs-Stage3 |
2.950400E-02 |
| Stage2-vs-Stage4 |
1.143680E-02 |
| Stage3-vs-Stage4 |
4.540200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.60270000054896E-07 |
| Normal-vs-AfricanAmerican |
1.349730E-02 |
| Normal-vs-Asian |
6.54389999965588E-07 |
| Caucasian-vs-AfricanAmerican |
1.990410E-01 |
| Caucasian-vs-Asian |
5.868800E-01 |
| AfricanAmerican-vs-Asian |
1.281220E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.3796999986937E-08 |
| Normal-vs-Female |
2.26719999996128E-06 |
| Male-vs-Female |
4.001200E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.34910000002287E-06 |
| Normal-vs-Age(41-60Yrs) |
7.00690000021709E-07 |
| Normal-vs-Age(61-80Yrs) |
5.40690000550015E-08 |
| Normal-vs-Age(81-100Yrs) |
1.311710E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.442400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.185500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.101400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.112600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.704200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.772400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.14400000000592E-05 |
| Classical-VS-Follicular |
1.532240E-01 |
| Classical-VS-Other |
3.076600E-01 |
| Classical-VS-Normal |
8.40679999947191E-07 |
| Tall-VS-Follicular |
3.76349999999803E-05 |
| Tall-VS-Other |
5.056000E-01 |
| Tall-VS-Normal |
1.20690013538649E-10 |
| Follicular-VS-Other |
2.201200E-01 |
| Follicular-VS-Normal |
3.774900E-04 |
| Other-VS-Normal |
1.793280E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.35370000045698E-07 |
| Normal-vs-N1 |
2.64019999973719E-07 |
| N0-vs-N1 |
1.068170E-01 |
|
|
